Payment overview · 2025
General Payments
$745.13
46 reported records · 11 companies
Healthcare provider profile · identity verified
Kevin Farthing, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PRESTONSBURG, KY · NPI 1629424429
Verified facts
What the public records show
CMS Open Payments records show Kevin Farthing, D.O. received $745.13 in general payments during 2025 across 46 reported records.
ABBVIE INC. accounted for 54.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Nurtec Odt, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $404.68 | 54.3% | 29 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $91.13 | 12.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.08 | 7.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.46 | 5.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.44 | 4.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.57 | 3.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.68 | 3.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.99 | 2.5% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $18.72 | 2.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.52 | 2.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.86 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $700.13 | 45 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $343.86 | 25 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $285.51 | 20 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $55.27 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.46 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $35.86 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.44 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $34.44 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $11.30 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $11.30 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 78 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 127 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
78 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
127 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
118 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 603 | 117 |
| Atorvastatin Calcium | Atorvastatin Calcium | 487 | 116 |
| Pantoprazole Sodium | Pantoprazole Sodium | 486 | 106 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 469 | 119 |
| Montelukast Sodium | Montelukast Sodium | 462 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 401 | 89 |
| Lisinopril | Lisinopril | 362 | 91 |
| Potassium Chloride | Potassium Chloride | 336 | 75 |
| Omeprazole | Omeprazole | 300 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 277 | 57 |
| Losartan Potassium | Losartan Potassium | 272 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 268 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 251 | 59 |
| Metformin Hcl | Metformin Hcl | 249 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 214 | 47 |
| Famotidine | Famotidine | 200 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 185 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 185 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 171 | 32 |
| Furosemide | Furosemide | 168 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 164 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 46 |
| Gabapentin | Gabapentin | 153 | 25 |
| Buspirone Hcl | Buspirone Hcl | 142 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 136 | 35 |
| Farxiga | Dapagliflozin Propanediol | 132 | 27 |
| Mounjaro | Tirzepatide | 127 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 123 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 122 | 29 |
| Eliquis | Apixaban | 118 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 115 | 24 |
| Clonazepam | Clonazepam | 112 | 15 |
| Glipizide | Glipizide | 112 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 26 |
| Carvedilol | Carvedilol | 104 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 104 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 25 |
| Ozempic | Semaglutide | 104 | 20 |
| Allopurinol | Allopurinol | 102 | 21 |
| Valsartan | Valsartan | 99 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 19 |
| Ibuprofen | Ibuprofen | 96 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 94 | 36 |
| Sertraline Hcl | Sertraline Hcl | 93 | 20 |
| Celecoxib | Celecoxib | 92 | 24 |
| Ezetimibe | Ezetimibe | 87 | 19 |
| Simvastatin | Simvastatin | 87 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 14 |
| Sucralfate | Sucralfate | 83 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 83 | 18 |
| Jardiance | Empagliflozin | 82 | 17 |
| Meloxicam | Meloxicam | 82 | 22 |
| Trazodone Hcl | Trazodone Hcl | 80 | 21 |
| Linzess | Linaclotide | 78 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 19 |
| Pregabalin | Pregabalin | 74 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 72 | 19 |
| Azelastine Hcl | Azelastine Hcl | 65 | 19 |
| Finasteride | Finasteride | 60 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 15 |
| Bumetanide | Bumetanide | 58 | 14 |
| Januvia | Sitagliptin Phosphate | 57 | 15 |
| Glyburide | Glyburide | 56 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 53 | suppressed |
| Synthroid | Levothyroxine Sodium | 53 | 13 |
| Aripiprazole | Aripiprazole | 50 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 41 |
| Methocarbamol | Methocarbamol | 50 | suppressed |
| Methylprednisolone | Methylprednisolone | 50 | 45 |
| Promethazine Hcl | Promethazine Hcl | 49 | 12 |
| Bupropion Xl | Bupropion Hcl | 48 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 21 |
| Donepezil Hcl | Donepezil Hcl | 45 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 44 | suppressed |
| Baclofen | Baclofen | 43 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Alprazolam | Alprazolam | 42 | suppressed |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | 14 |
| Trulicity | Dulaglutide | 40 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | 12 |
| Lactulose | Lactulose | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 13 |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Azithromycin | Azithromycin | 23 | 20 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Naproxen | Naproxen | 23 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Desloratadine | Desloratadine | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 18 |
| Spironolactone | Spironolactone | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 14 |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $745.13 · 46 records | ABBVIE INC. | BOTOX, CREON, FREESTYLE LIBRE 3, KESIMPTA, Korlym, LEQEMBI, LINZESS, MOUNJARO, NURTEC ODT, QULIPTA, SPRAVATO, TRELEGY ELLIPTA, TYSABRI, UBRELVY, VUMERITY, VYEPTI, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error